secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENEREX PHARMA, INC. (RGPX)
CIK:        0001357878
Form:       8-K
Filed at:   2022-01-18T23:59:59+00:00
Accession:  0001472375-22-000008
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

RegeneRex Pharma appoints Troy Thuet as COO; Dr. Lee Ori becomes Chief R&D Officer
--------------------------------------------------------------------------------

- Troy Thuet appointed COO effective Jan 14, 2022; over 15 years of managerial and executive experience.
- Dr. Lee Ori transitions from COO to Chief R&D Officer; holds PharmD from Auburn, formerly at Eli Lilly.
- No departure or compensation details disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357878/000147237522000008/0001472375-22-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357878/000147237522000008/ixform8k.htm
  HTML page:      https://secwatch.observer/filing/0001472375-22-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer